<DOC>
	<DOCNO>NCT01420692</DOCNO>
	<brief_summary>The main purpose study analyze effect addition sulfonylurea ( gliclazide MR ) , alternatively , basal insulin ( insulin detemir ) life-style modification metformin treatment second step treatment type 2 diabetes mellitus endothelial cell function . The second goal identify effect treatment alternative body-mass index , change body fat mass , insulin resistance insulin secretion capacity beta cell . The third aim study determine success rate treatment alternative glycemic control 6 month follow-up .</brief_summary>
	<brief_title>The Effects Insulin Detemir Gliclazide-MR Treatments Endothelial Functions Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The lack enough number randomize controlled study treatment type 2 diabetes important obstacle recommend single-drug combination treatment . The pleomorphic effect treatment choice control hyperglycemia type 2 diabetes equally important . There yet lack comparison different treatment alternative find treatment algorithms American Diabetes Association ( ADA ) term effect hyperglycemia control well pleomorphic effect . Some pleomorphic effect change body-mass index , insulin resistance , insulin secretion capacity effect endothelial function coagulation status . This study mainly prepare analyze effect addition sulfonylurea ( gliclazide MR ) alternatively basal insulin ( insulin detemir ) life-style modification metformin treatment second step treatment type 2 diabetes mellitus treatment algorithm endothelial cell function . The second goal identify effect treatment alternative body-mass index , change body fat mass , insulin resistance insulin secretion capacity beta cell . The third aim study determine success rate treatment alternative glycemic control 6 month follow-up . This study sense expect shed light decision best treatment option well essential contribution lack literature field . To reach aim , 20-65 year-old patient apply endocrinology metabolism outpatient unit , type 2 diabetes diagnosis unregulated blood glucose level first step treatment ( life-style modification metformin ) recruit randomize either Gliclazide MR arm Insulin Detemir arm . As soon patient arm reach target glycemic level ( 0. week ) , basal test show endothelial function well inflammatory coagulation status flow-mediated dilatation ( FMD ) investigation peripheral blood level TNF-α , IL-6 , MCP-1 , sICAM-1 , sVCAM-1 , vWF , E-selectin , P-selectin , endothelin-1 , PAI-1 , tPA HMW adiponectin perform . To investigate insulin resistance change insulin secretory capacity beta cell , mixed meal test perform data obtain glucose well insulin level mixed meal test evaluate . To identify change body-fat mass , bioimpedance analysis also perform . All basal test repeat study subject , 12 week 24 week reach target glycemic level . Patients randomized insulin detemir arm beginning gliclazide MR treatment 12.week test perform . The effect continuous gliclazide MR treatment early insulin detemir follow gliclazide MR treatment endothelial cell function , inflammation coagulation , insulin resistance , insulin secretory capacity beta cell body-fat mass evaluate compare 0. week 12. 24. week value within arm well 24. week value arm .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>1 . Type 2 diabetic patient use least 1000 mg/day metformin least 3 month 2 . 7 &lt; A1C ≤ 11 3 . Patients without previous use oral antidiabetic metformin insulin 4 . Between 20 65 year old male female patient 1 . Active hepatic disease 2 . Serum creatinin 1,5 mg/dl male , 1,4 female 3 . Proliferative Diabetic Retinopathy 4 . Coronary Artery Disease 5 . Patients kind diagnose malignancy 6 . Pregnancy Lactation 7 . Fasting Cpeptide level low 2.0 ng/ml 8 . Smoking drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Tip 2 DM</keyword>
	<keyword>Endothelium</keyword>
	<keyword>Gliclazide</keyword>
	<keyword>Insulin detemir</keyword>
</DOC>